A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Vigil 1.0 x 10e7 cells/injection, minimum of 4 to a maximum of 12 administrations.

oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)

irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously

675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days

75 mg/m2 IV administered on Day 8 and every 21 days